Skip to main content
Equibles
BIO logo

BIO · Bio-Rad Laboratories, Inc. · Metrics

Track BIO — free

Use BIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$372.00 +3.45 (+0.94%)
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$9.88B
Shares
26.74M

BIO metrics

80 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$368.55
Market cap
$9.88B

Price action

20 metrics
Price change (1W)
-4.5%
Price change (30D)
+3.7%
Price change (3M)
+27.4%
Price change (6M)
+41.1%
Price change (YTD)
+21.6%
Price change (1Y)
+31.5%
Trailing year
Price change (5Y)
-54.1%
52-week high
$390.34
52-week low
$241.71
Change from 52-week high
-5.6%
Change from 52-week low
+52.5%
Annualized volatility
37.2%
Annualized volatility (3M)
31.1%
Beta
0.8
RSI (14D)
51.1
Price vs SMA 50
+7.2%
Price vs SMA 200
+21.4%
Avg volume (3M)
290,358
Relative volume
1.0
Average dollar volume
$95.39M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
26.74M

Valuation

12 metrics
P / E (TTM)
45.0
Trailing earnings · reciprocal yield 2.2%
PEG ratio
2.4
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.8×
reciprocal yield 26.2%
P / book
1.4
reciprocal yield 72.6%
FCF yield
3.6%
TTM · current market cap
Buyback yield
1.3%
P / FCF
28.0
reciprocal yield 3.6%
P / operating cash flow
20.1
reciprocal yield 5.0%
Earnings yield
2.3%

Historical valuation

8 metrics
P / E historical average (3Y)
29.3×
reciprocal yield 3.4%
P / E historical average (5Y)
20.9×
reciprocal yield 4.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.3%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
51.9%
Operating margin
2.1%
Trailing 12 months
Net margin
8.6%
Gross profit (TTM)
$1.34B
Operating profit (TTM)
$53.10M
Net income (TTM)
$222.40M
Trailing 12 months
Diluted EPS (TTM)
$8.19
FCF margin
13.6%
Effective tax rate
36.5%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$46.45

Growth

11 metrics
Revenue growth YoY
-0.1%
Year over year
Net income growth YoY
+16.9%
Revenue (TTM)
$2.59B
Trailing 12 months
EPS growth YoY
+18.7%
Shares change YoY
-1.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-2.7%
Revenue CAGR (5Y)
+0.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-26.1%
FCF CAGR (3Y)
+66.2%
FCF CAGR (5Y)
-4.7%

Quality

14 metrics
Return on equity
3.1%
Return on assets
2.2%
Debt / equity
—
Current ratio
3.1
EBITDA (TTM)
$382.33M
Free cash flow (TTM)
$353.10M
Quick ratio
2.3
Interest coverage
1.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$517.00M
Total assets
$10.25B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$492.60M
Capital expenditures (TTM)
$139.50M
R&D (TTM)
$265.70M
SG&A (TTM)
$852.20M
Stock compensation (TTM)
$60.30M
R&D / revenue
10.3%
Stock compensation / revenue
2.3%

Ownership (13F)

3 metrics
13F filers
400
13F filer change QoQ
+1
Institutional ownership
72.8%

Short interest

3 metrics
Short interest
4.2%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 12208 CUSIP 090572207 13F (30d) 18 filings 17 filers Visit website Investor relations